| Fund | Shares Held | Position Value | Action (latest Q) |
|---|---|---|---|
| Maverick Capital Lee Ainslie | 1.64M | $41.11M | NEW |
| D.E. Shaw David Shaw | 832K | $20.80M | NEW |
| Citadel Ken Griffin | 580K | $14.50M | NEW |
| Renaissance Technologies Jim Simons (founder) | 279K | $6.99M | NEW |
| Marshall Wace | 216K | $5.41M | NEW |
Centessa Pharmaceuticals plc American Depositary Receipt represents shares in Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company headquartered in Altrincham, United Kingdom, and founded in 2020. The company discovers and develops innovative medicines to address high unmet needs in various therapeutic areas, including oncology, hematology, immunology, inflammation, neuroscience, and rare diseases. Its pipeline features a diverse portfolio of uncorrelated programs ranging from preclinical to Phase 3 stages, such as SerpinPC targeting Hemophilia A and B, LB101 for solid tumors, ORX750 for Narcolepsy Type 1 and other sleep disorders, MGX292 for Pulmonary Arterial Hypertension, and additional undisclosed assets for solid tumors. ORX142, a novel Orexin Receptor 2 agonist, is advancing in clinical development with recent FDA clearance for Phase 1 studies. Centessa Pharmaceuticals plc focuses on delivering transformational therapies through its integrated platform, emphasizing orexin receptor agonists and other novel mechanisms to treat complex diseases like sleep disorders and beyond.
Earnings calendar coming soon. Subscribe to get notified when CNTA reports next.
Get earnings alerts →